Exagen to Announce First Quarter Financial Results on May 11, 2020
April 27 2020 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it will release financial results for the
quarter ended March 31, 2020 after the market closes on Monday, May
11, 2020. Ron Rocca, President and Chief Executive Officer, and
Kamal Adawi, Chief Financial Officer, will host a conference call
to review the Company’s results at 4:30 PM Eastern Time (1:30 PM
Pacific Time).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international).
Participants wishing to access the call via webcast should
use the link posted on the Exagen investor relations website at
https://investors.exagen.com/
A replay of the conference call will be available until Monday,
May 18, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific Time).
Interested parties may access the replay of the conference call by
dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international)
using passcode 13701300. Additionally, a recording of the
webcast will be available using the link on the Exagen investor
relations website 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
Investors
Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
Exagen Inc. Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024